We Develop High-Quality Biosimilars. For Better Access to Vital Medicines.

Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company's activities span the entire range from technical-pharmaceutical development to clinical trials, all the way through to preparation of dossiers for regulatory approval.

Annual Report 2024

Formycon. The Biosimilar Experts.

Sustainability at Formycon

Our Strategy and Areas of Action

Discover Formycon

Biosimilar developer with unique expertise

Latest News

Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position

March 27, 2025

Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025

March 24, 2025

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union

March 03, 2025

Meet your New Colleagues

Formycon’s employees are the foundation of our success. We strongly believe that an appreciative corporate culture contributes significantly to our progress. Therefore, we cultivate a culture of diversity and mutual appreciation.

We offer you the opportunity for rapid career advancement in a dynamic, high-growth environment where professionalism and team spirit form the foundation of our daily cooperation.

Explore your career opportunities

Facts & Insights

Key Figures

Biosimilar Pipeline

Product	Originator	Preclinical Phase	Clinical Phase I	Clinical Phase III
FYB201	Lucentis®
FYB202	Stelara®
FYB203	Eylea®
FYB206	Keytruda®
FYB208	undisclosed
FYB209	undisclosed
FYB210	undisclosed